Cencora boosted adjusted EPS guidance and announced share repurchases after Q2 earnings beat, despite lowering revenue growth forecasts.
Cencora reported fiscal Q2 adjusted diluted EPS of $4.75, up 7.5% year-over-year, and adjusted operating income growth of 6%. Free cash flow remained strong at $1.1 billion for the quarter.
The company raised its full-year adjusted EPS guidance to a range of $17.65-$17.90 and announced plans to resume opportunistic share repurchases, targeting $1 billion by year-end. However, revenue growth guidance was cut to 4%-6% from 7%-9%, citing faster brand conversions at a large mail-order pharmacy customer and slower GLP-1 product growth.
Management highlighted solid performance in both U.S. and International Healthcare Solutions segments, reaffirming confidence in fiscal 2026 guidance.